Supreme Court Declines To Hear Cardizem CD, Hytrin Antitrust Cases
This article was originally published in The Pink Sheet Daily
Executive Summary
The two cases created an apparent disagreement among the federal appellate circuits on the legality of “reverse payments” from a brand company to delay a generic’s entry.